Hypophosphatasia Epidemiology Forecast Report 2034: Focus On United States, Germany, France, Italy, Spain, United Kingdom, And Japan

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Hypophosphatasia - Epidemiology Forecast-2034" report has been added to ResearchAndMarkets.com's offering.

The "Hypophosphatasia - Epidemiology Forecast - 2034" report delivers an in-depth understanding of hypophosphatasia, historical and forecasted epidemiology of hypophosphatasia in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
For the purpose of designing the patient-based model for hypophosphatasia, the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of hypophosphatasia, and severity-specific diagnosed prevalent cases of hypophosphatasia in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
According to the epidemiology model, in the 7MM, the total diagnosed prevalent cases of hypophosphatasia were 6,193 in 2023, which are expected to increase at a CAGR of 0.8% by 2034. In 2023, there were 780 mild cases, 4,736 moderate cases, and 56 severe cases of hypophosphatasia reported in the US, based on severity-specific diagnosed prevalence. These numbers are projected to increase to 784 mild cases, 4,760 moderate cases, and 56 severe cases by 2034.

In EU4 and the UK, the total diagnosed prevalent cases of hypophosphatasia were 481 in 2023. Of these, nearly 122 cases were found in Germany, followed by 119 cases in France and 117 in the UK. These cases are expected to change during the study period. Japan had the second-highest number of diagnosed prevalent cases of hypophosphatasia among the 7MM, with 141 cases in 2023.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Children's Mercy Research Institute in Kansas City, Missouri, Universitaisklinikum Wurzburg, Osaka University Graduate School of Medicine, and Soft Bones, S. Andrea Hospital, Diabetes Unit, Italy University of Tokyo Hospital, Japan and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

The prevalence of severe hypophosphatasia is approximately 1 in every 100,000 live births. Though the exact numbers are unknown, it is believed nearly 1 in every 200 may be carriers of the hypophosphatasia gene in the US. About 50% of individuals with persistently low alkaline phosphatase (ALP) levels have mutations in the TNSALP gene, with enzyme activity decreasing with each mutation. Haploinsufficiency alone can lower blood ALP levels, and approximately 50% of patients with these mutations show a buildup of phosphorylated substrates. This indicates a significant genetic component in hypophosphatasia.

Key Highlights

• The analysis projects that in 2023, there were 6,193 diagnosed prevalent cases of hypophosphatasia in the 7MM. This number is expected to grow at a compound annual growth rate (CAGR) of 0.8%, reaching approximately 6,219 cases by 2034. The increase is attributed to enhanced genetic screening and greater awareness and education about the condition.
• In the US, there were 5,572 total diagnosed prevalent cases of hypophosphatasia in 2023; which are expected to increase at a CAGR of 0.9% to 5,600 by 2034.
• Among the EU4 countries and the UK, Germany had the highest number of severity-specific diagnosed prevalent cases of hypophosphatasia, with 16 mild cases, 103 moderate cases, and 3 severe cases. In contrast, Spain had the lowest number, with 7 mild cases, 46 moderate cases, and 1 severe case in 2020.
• Among the 7MM, in 2023, Japan accounted for nearly 141 cases, which was nearly 2.3% of the total diagnosed prevalent cases of hypophosphatasia in the 7MM.
• The analysis indicates that in 2023, Japan, accounted for approximately 17 mild cases, 119 moderate cases, and 5 severe cases diagnosed as prevalent cases of hypophosphatasia. This is expected to change by 2034.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of hypophosphatasia, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of hypophosphatasia? What will be the growth opportunities across the 7MM concerning the patient population of hypophosphatasia?
• What is the historical and forecasted hypophosphatasia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Why are the total cases of Hypophosphatasia in Japan lower than in the US?
• Which country has a high patient share for hypophosphatasia?

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Hypophosphatasia in 2020
3.2. Patient Share (%) Distribution of Hypophosphatasia in 2034
4. Epidemiology Methodology
5. Executive Summary
6. Disease Background and Overview
6.1. Introduction to Hypophosphatasia
6.2. Classification
6.3. Clinical Features
6.4. Signs and Symptoms
6.5. Causes
6.6. Pathophysiology
6.7. Genetic Aspect of Hypophosphatasia
6.8. Diagnosis
6.8.1. Diagnostic Guidelines
6.8.1.1. Japanese Guidelines for Diagnosis of Hypophosphatasia
6.8.2. Diagnostic Criteria
6.8.2.1. Hypophosphatasia diagnosis: current state-of-the-art and proposed diagnostic criteria for children and adults
7. Patient Journey
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. Total Diagnosed Prevalent Cases of Hypophosphatasia
8.2.2. Severity-specific Diagnosed Prevalent Cases of Hypophosphatasia
8.3. Total Diagnosed Prevalent Cases of Hypophosphatasia in the 7MM
8.4. The US
8.4.1. Total Diagnosed Prevalent Cases of Hypophosphatasia in the US
8.4.2. Severity-specific Diagnosed Prevalent Cases of Hypophosphatasia in the US
8.5. EU4 and the UK
8.5.1. Total Diagnosed Prevalent Cases of Hypophosphatasia in EU4 and the UK
8.5.2. Severity-specific Diagnosed Prevalent Cases of Hypophosphatasia in EU4 and the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of Hypophosphatasia in Japan
8.6.2. Severity-specific Diagnosed Prevalent Cases of Hypophosphatasia in Japan
9. Patient Journey
10. KOL Views
11. Appendix
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

MENAFN18122024004107003653ID1109007780